GlaxoSmithKline and Johnson & Johnson have settled a short-lived legal spat over GSK's allergy drug marketing claims--meaning that now, the only battle left will be the one for market share.
A deal's done: Less than a month after receiving Novartis' stall of vaccines products, GlaxoSmithKline has ended the yearlong pricing standoff with the United Kingdom's National Health Service over meningitis B vaccine Bexsero.
A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.
Swiss-based Actelion Pharmaceuticals was granted marketing approval by Japan's Ministry of Health, Labour and Welfare for Opsumit (macitentan) for the treatment of pulmonary arterial hypertension (PAH).
GlaxoSmithKline is looking for some new partners in academia, launching a contest for would-be collaborators with early-stage projects that could translate into marketable medicines.
Last year, GlaxoSmithKline announced plans to slim down its Research Triangle Park, NC-based operations, chopping 900 jobs. Now, it's telling state officials that almost 200 workers are heading for the door.
It's been 7 months since price negotiations over meningitis B vaccine Bexsero began between Novartis and the U.K. government. And as far as new owner GlaxoSmithKline is concerned, that's long enough.
GlaxoSmithKline has reached out to the storied Cold Spring Harbor Laboratory to collaborate on a potential treatment for Type 2 diabetes and obesity, inking a multiyear R&D deal.
Novartis may have spent 7 months negotiating fruitlessly with the U.K. government over the price of meningitis B vaccine Bexsero, but now that the product is in GlaxoSmithKline's hands, its new owner intends to do no such thing.
Good news for GlaxoSmithKline: An FDA panel of experts says the efficacy and safety data for blockbuster wannabe Breo support the asthma indication it's gunning for in adults 18 and older. When it comes to children aged 12 to 17, though? The panelists aren't having it.